Literature DB >> 27699031

Outpatient management without initial assessment for febrile patients undergoing adjuvant chemotherapy for breast cancer.

Kosei Kimura1, Satoru Tanaka2, Mitsuhiko Iwamoto1, Hiroya Fujioka1, Nayuko Sato1, Risa Terasawa1, Kanako Kawaguchi1, Junna Matsuda1, Nodoka Umezaki1, Kazuhisa Uchiyama1.   

Abstract

The purpose of this study was to retrospectively analyze the feasibility of outpatient management without initial assessment for febrile patients undergoing adjuvant chemotherapy for breast cancer. A total of 131 consecutive patients with breast cancer treated with adjuvant or neoadjuvant chemotherapy from 2011 to 2013 at Osaka Medical College Hospital (Osaka, Japan) were retrospectively reviewed. In the case of developing a fever (body temperature, ≥38°C), the outpatients had been instructed to take previously prescribed oral antibiotics for 3 days without any initial assessment, and if no improvement had occurred by then, they were required to visit the hospital for examination and to undergo treatment based on the results of a risk assessment for complications. The primary aim of the present study was to assess the outcome of febrile episodes, while the secondary aim was to assess the incidence of febrile episodes, hospitalizations, and the type of chemotherapy. The 131 patients received 840 chemotherapy administrations. Fifty-five patients (42.0%) had a total of 75 febrile episodes after 840 chemotherapy administrations (8.9%). Treatment failure occurred in 12 of the 75 episodes (16.0%) in 11 of the 55 patients (20.0%). Only four episodes required hospitalization. Treatment success was achieved in 63 episodes (84.0%). In conclusion, the feasibility of outpatient management without initial assessment was evaluated in the present study for febrile patients undergoing adjuvant chemotherapy for breast cancer, and the outpatient strategy regimen may be safe and convenient for these patients.

Entities:  

Keywords:  adjuvant chemotherapy; breast cancer; febrile neutropenia; oral antibiotics; outpatient management

Year:  2016        PMID: 27699031      PMCID: PMC5038204          DOI: 10.3892/mco.2016.992

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  20 in total

1.  The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephone.

Authors:  Toshiro Mizuno; Noriyuki Katsumata; Hirofumi Mukai; Chikako Shimizu; Masashi Ando; Toru Watanabe
Journal:  Support Care Cancer       Date:  2006-08-29       Impact factor: 3.603

2.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

Review 3.  Management of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropenia.

Authors:  Caterina Fontanella; Silvia Bolzonello; Bianca Lederer; Giuseppe Aprile
Journal:  Breast Care (Basel)       Date:  2014-04       Impact factor: 2.860

4.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

5.  Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin.

Authors:  Georgios Chamilos; Aristotle Bamias; Eleni Efstathiou; Pagona M Zorzou; Efstathios Kastritis; Evagelos Kostis; Christos Papadimitriou; Meletios A Dimopoulos
Journal:  Cancer       Date:  2005-06-15       Impact factor: 6.860

6.  The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

Authors:  J Klastersky; M Paesmans; E B Rubenstein; M Boyer; L Elting; R Feld; J Gallagher; J Herrstedt; B Rapoport; K Rolston; J Talcott
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

7.  Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients.

Authors:  O Teuffel; S Cheng; M C Ethier; C Diorio; J Martino; C Mayo; R Wing; L Sung; S M H Alibhai
Journal:  Support Care Cancer       Date:  2012-02-17       Impact factor: 3.603

8.  A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia.

Authors:  Brian Dulisse; Xiaoyan Li; Julie A Gayle; Richard L Barron; Frank R Ernst; Kenneth J Rothman; Jason C Legg; James A Kaye
Journal:  J Med Econ       Date:  2013-04-12       Impact factor: 2.448

9.  [A general description of the clinical guideline for the management of febrile neutropenia].

Authors:  Yasushi Takamatsu
Journal:  Gan To Kagaku Ryoho       Date:  2013-06

10.  Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge.

Authors:  Catherine Sebban; Sophie Dussart; Christine Fuhrmann; Hervé Ghesquieres; Isabelle Rodrigues; Lionel Geoffrois; Yves Devaux; Laurence Lancry; Giselle Chvetzoff; Thomas Bachelot; Maria Chelghoum; Pierre Biron
Journal:  Support Care Cancer       Date:  2008-01-15       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.